The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    SELECT and the effect of selenium on prostate cancer risk

    Dr. Jodi Walker at the VA Medical Center, in Bath, New York has summarized the results of SELECT (The Selenium and Vitamin E Cancer Prevention Trial), which studied selenium (L-selenomethionine) and vitamin E alone or combined to lower the risk of prostate cancer.

    Let’s summarize her summary.

    First, the details.

    • Over 35,000 men were randomly assigned to 1 of 4 groups.
      • Selenium 200 mcg/day
      • Vitamin E 400 IU/day
      • Selenium + vitamin E
      • Placebo
    • All participants were 55 years or older, except for African American men, who were 50 years or older.
    • All participants had prostate-specific antigen (PSA) blood levels of 4 ng/mL or less, no history of prostate cancer, and negative results on digital rectal examination.
    • Patients were followed for about 5.5 years.

    And, the results.

    • Prostate cancer was detected in 4.6% and 4.4% of the selenium and placebo groups, respectively–not significant.
    • SELECT was scheduled to run through 2012, but it was cut short because no correlation between taking selenium and prevention of prostate cancer was found.

    The bottom line?

    Some smaller studies suggest a benefit from selenium, says Dr. Walker, but in this large group of men, “taking into consideration the side effects associated with antioxidants and the risk for drug-drug interactions, other options at this point prove to be more beneficial for prostate cancer prevention.”

    6/6/10 15:18 JR

    Leave a Comment

    You must be logged in to post a comment.